Canertinib

Category	Orthopoxvirus
CAS	267243-28-7
Description	Canertinib is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 = 0.8 nM), HER-2 (IC50 = 19 nM) and ErbB-4 (IC50 = 7 nM).

Quotation Now

Product Information

Synonyms	CI-1033; PD-183805; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide; 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-
IUPAC Name	N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
Molecular Weight	485.94
Molecular Formula	C24H25ClFN5O3
Canonical SMILES	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI	InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
InChIKey	OMZCMEYTWSXEPZ-UHFFFAOYSA-N
Boiling Point	691.0±55.0°C (Predicted)
Melting Point	188-190°C
Flash Point	371.7±31.5 °C
Purity	>98%
Density	1.355±0.06 g/cm3 (Predicted)
Solubility	Soluble in DMSO, Methanol
Appearance	Pale Yellow Solid
Storage	Store at -20°C
Complexity	671
Exact Mass	485.1629955
Index Of Refraction	1.650
In Vitro	Canertinib significantly inhibits growth of cultured melanoma cells, RaH3 and RaH5, in a dose-dependent manner. IC50 is approximately 0.8 μM and by 5μM both cell lines are completely growth-arrested within 72 h of treatment. Incubation of exponentially growing RaH3 and RaH5 with 1 μM canertinib accumulated the cells in the G1-phase of the cell cycle within 24 h of treatment without induction of Apoptosis. 1 μM canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-, Erk1/2- and Stat3 activity in both cell lines. Canertinib also is a potent activator of exosome secretion.
In Vivo	Canertinib shows superior in vivo antitumor activity, giving growth delays in A431 xenografts exceeding 50 days following oral administration. The growth of human malignant melanoma xenografts, RaH3 and RaH5, in nude mice is significantly inhibited by i.p. injections of 40 mg/kg/day canertinib. The anti-proliferative effect on melanoma xenografts is visible already within 4 days of treatment and further increased throughout the treatment period as observed through the differences in tumor volumes, reaching statistical significance within 18 days of treatment.
PSA	88.61000
Target	EGFR: 7.4 nM (IC50) ErbB: 29 nM (IC50)
Vapor Pressure	0.0±2.2 mmHg at 25°C
XLogP3-AA	3.9